Login / Signup

Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.

Zhanna KaidarovaClara DiGermanioBrian S CusterPhillip J Norris
Published in: Transfusion (2023)
The data do not support the conclusion that Mirasol exerted a protective effect against alloimmunization after platelet transfusion in the MIPLATE trial.
Keyphrases
  • sickle cell disease
  • phase iii
  • study protocol
  • electronic health record
  • cardiac surgery
  • clinical trial
  • big data
  • randomized controlled trial
  • acute kidney injury
  • open label
  • machine learning
  • red blood cell